SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway. - He, Chunxiao; Yu, Jiaying; Mao, Shuang; Yang, Shaohua; Jiang, Xianming; Huang, Lei; Li, Mingzhe; He, Yulong; Zhang, Xinhua; Xiang, Xi (Clinical & Translational Medicine, 2025)